A Chinese herbal formula Kesuting Syrup against COVID‐19: Leveraging multidimensional computations in network pharmacology‐driven experimental and clinical trials

The manuscript shared the published baseline data of the same patient population.3 For the Omicron branch, the conventional therapy given in the National guideline for COVID-19 management (Version 9) was combined with Kesuting Syrup (Guizhou Bailing Group Pharmaceutical Co., Ltd., Approval No.: GYZZ Z20025238) in the experimental group (100 mL per bottle, taken orally, three times a day, 20 mL each time). Regarding the results, for the original branch in the clinical trial, there was no statistical difference between Kesuting and the control branch in terms of recovery time and recovery rate (negative within 7 days after infection) (p > .05). [...]Kesuting Syrup can clinically improve recovery time and rate in patients with SARS-CoV-2 mild Omicron variant infection. [...]the symptomatic improvement of Kesuting Syrup, while it may not significantly influence viral replication, can be an adjunct to standard care in managing patient comfort and may indirectly impact recovery metrics of COVID-19.